National Institutes of Health, 55859-55860 [E8-22611]

Download as PDF Federal Register / Vol. 73, No. 188 / Friday, September 26, 2008 / Notices Bethesda, MD 20892–5452, (301) 594–8898, barnardm@extra.niddk.nih.gov. Name of Committee: National Institute of Diabetes and Digestive and Kidney Diseases Special Emphasis Panel, Translational Research. Date: October 29, 2008. Time: 8 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: Bethesda Marriott, 5151 Pooks Hill Road, Bethesda, MD 20814. Contact Person: Michele L. Barnard, PhD, Scientific Review Officer, Review Branch, DEA, NIDDK, National Institutes of Health, Room 753, 6707 Democracy Boulevard, Bethesda, MD 20892–5452, (301) 594–8898, barnardm@extra.niddk.nih.gov. Name of Committee: National Institute of Diabetes and Digestive and Kidney Diseases Special Emphasis Panel, Gastrointestinal Programs. Date: November 13, 2008. Time: 7:45 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: Holiday Inn National Airport, 2650 Jefferson Davis Highway, Arlington, VA 22202. Contact Person: Michael W. Edwards, PhD, Scientific Review Officer, Review Branch, DEA, NIDDK, National Institutes of Health, Room 750, 6707 Democracy Boulevard, Bethesda, MD 20892–5452, (301) 594–8886, edwardsm@extra.niddk.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.847, Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology and Hematology Research, National Institutes of Health, HHS) Dated: September 18, 2008. Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. E8–22605 Filed 9–25–08; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health jlentini on PROD1PC65 with NOTICES National Institute of Mental Health; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant VerDate Aug<31>2005 18:07 Sep 25, 2008 Jkt 214001 applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Mental Health Special Emphasis Panel, ITVC Conflicts. Date: October 15, 2008. Time: 10 a.m. to 12 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852. (Telephone Conference Call) Contact Person: Enid Light, PhD, Scientific Review Administrator, Division of Extramural Activities, National Institute of Mental Health, NIH, Neuroscience Center, 6001 Executive Boulevard, Room 6132, MSC 9608, Bethesda, MD 20852–9608, 301–443– 0322, elight@mail.nih.gov. Name of Committee: National Institute of Mental Health Special Emphasis Panel, National Research Service Award (NRSA) Institutional Research Training Grants. Date: October 20, 2008. Time: 8 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: Embassy Suites Hotel, 4300 Military Road, Washington, DC 20015. Contact Person: Vinod Charles, PhD, Scientific Review Administrator, Division of Extramural Activities, National Institute of Mental Health, NIH, Neuroscience Center, 6001 Executive Blvd., Room 6151, MSC 9606, Bethesda, MD 20892–9606, 301–443–1606. Name of Committee: National Institute of Mental Health Special Emphasis Panel, Pathway to Independence (PI) Award. Date: October 28, 2008. Time: 8 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 Wisconsin Avenue, Bethesda, MD 20814. Contact Person: Megan Libbey, PhD, Scientific Review Administrator, Division of Extramural Activities, National Institute of Mental Health, NIH, Neuroscience Center, 6001 Executive Blvd., Room 6148, MSC 9609, Rockville, MD 20852, 301–402–6807, libbeym@mail.nih.gov. Name of Committee: National Institute of Mental Health Special Emphasis Panel Aids Applications. Date: November 15, 2008. Time: 10 a.m. to 12 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852. (Telephone Conference Call) Contact Person: Enid Light, PhD, Scientific Review Administrator, Division of Extramural Activities, National Institute of Mental Health, NIH, Neuroscience Center, 6001 Executive Boulevard, Room 6132, MSC 9608, Bethesda, MD 20852–9608, 301–443– 0322, elight@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.242, Mental Health Research Grants; 93.281, Scientist Development PO 00000 Frm 00049 Fmt 4703 Sfmt 4703 55859 Award, Scientist Development Award for Clinicians, and Research Scientist Award; 93.282, Mental Health National Research Service Awards for Research Training, National Institutes of Health, HHS) Dated: September 18, 2008. Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. E8–22607 Filed 9–25–08; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Prospective Grant of Exclusive License: Use of Benztropinamine Analogs To Treat Psychiatric and Neurological Disorders National Institutes of Health, Public Health Service, HHS. ACTION: Notice. AGENCY: SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR Part 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the inventions embodied in U.S. Patent Application No. 60/689,746, filed June 10, 2005, now abandoned [HHS Ref. No. E–089– 2005/0–US–01]; PCT Patent Application No. PCT/US2006/22401, filed June 7, 2006, now abandoned [HHS Ref. No. E– 089–2005/0–US–02]; U.S. Patent Application No. 11/917,036, filed December 10, 2007 [HHS Ref. No. E– 089–2005/0–US–03]; European Patent Application No. 06772641.4, filed December 7, 2007, which published as 1888064 on February 20, 2008 [HHS Ref. No. E–089–2005/0–EP–04]; Australian Patent Application No. 2006258035, filed November 30, 2007 [HHS Ref. No. E–089–2005/0–AU–05]; Japanese Patent Application No. 2008– 515947, filed December 7, 2007 [HHS Ref. No. E–089–2005/0–JP–06]; and Canadian Patent Application No. 2609577, filed November 23, 2007 [HHS Ref. No. E–089–2005/0–CA–07], all of which are entitled ‘‘Benztropinamine Analogs as Dopamine Uptake Inhibitors’’ (Inventors: Amy Newman and Jonathan Katz, NIDA) to Shire LLC, having an office in at least Basingstoke, United Kingdom. The patent rights in these inventions have been assigned to the United States of America. The prospective exclusive license territory may be worldwide, and the field of use may be limited to the use of benztropinamine analogs, E:\FR\FM\26SEN1.SGM 26SEN1 jlentini on PROD1PC65 with NOTICES 55860 Federal Register / Vol. 73, No. 188 / Friday, September 26, 2008 / Notices specifically, compounds derived from Formula I, wherein B is NR 4 and wherein R 4 is not CH3 (methyl group) to treat psychiatric and neurological disorders. DATES: Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before November 25, 2008 will be considered. ADDRESSES: Requests for copies of the patent application, inquiries, comments, and other materials relating to the contemplated exclusive license should be directed to: Charlene A. Sydnor, Ph.D., Technology Licensing Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852–3804; Telephone: (301) 435– 4689; Facsimile: (301) 402–0220; e-mail: sydnorc@mail.nih.gov. SUPPLEMENTARY INFORMATION: This technology relates to the synthesis of novel dopamine transport inhibitors and their use to treat mental disorders. The inventors developed benztropinamine analogs by replacing the benzhydrylether moiety of benztropine and its analogs with the isosteric benzhydrylamine system in order to produce more stable compounds with increased solubility and bioavailability for improved therapeutic formulation and utility. These compounds have a high affinity for the dopamine transporter and inhibit dopamine uptake, but do not produce a significant stimulation of locomotor activity or cocaine-like subjective effects in a drug discrimination model. These compounds are useful for the treatment of mental disorders such as conduct disorders, alcohol addiction, tobacco addiction, nicotine addiction, drug addiction, sleep disorders, inhalation disorders, Parkinsonism including Parkinson’s disease, female and male orgasmic disorders, female and male sexual arousal disorders, hypoactive sexual desire disorders, and anxiety and/or depression disorders. These compounds are also useful as imaging probes for detecting cocaine binding sites, as well as monitoring or diagnosing Parkinson’s disease. The prospective exclusive license will be royalty bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR Part 404.7. The prospective exclusive license may be granted unless within sixty (60) days from the date of this published notice, the NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR Part 404.7. VerDate Aug<31>2005 18:07 Sep 25, 2008 Jkt 214001 Applications for a license in the field of use filed in response to this notice will be treated as objections to the grant of the contemplated exclusive license. Comments and objections submitted to this notice will not be made available for public inspection and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552. Dated: September 17, 2008. Richard U. Rodriguez, Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health. [FR Doc. E8–22611 Filed 9–25–08; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HOMELAND SECURITY [Docket No. DHS–2008–0102] National Protection and Programs Directorate; Designation of the SectorSpecific Agency for the Critical Manufacturing Sector and Resulting Changes in the National Infrastructure Protection Plan National Protection and Programs Directorate, Office of Infrastructure Protection, DHS. ACTION: Notice of Sector Specific Agency designation for Critical Manufacturing. AGENCY: SUMMARY: This notice informs the public that the Secretary, Department of Homeland Security (DHS), has designated the DHS Office of Infrastructure Protection (IP) as the Sector-Specific Agency (SSA) for the Critical Manufacturing Sector under the National Infrastructure Protection Plan (NIPP). IP will now move forward with the organization and coordination processes identified in the NIPP for establishing a new critical infrastructure and key resources (CIKR) sector. These initial steps will include establishing Government and Sector Coordinating Councils, which will begin the process of full integration into the CIKR Sector Partnership, implementation of the NIPP Risk Management Framework and development of the Critical Manufacturing Sector Specific Plan. This designation also includes language changes to the NIPP identifying the new sector, which will take affect immediately and remain in effect until the NIPP is rewritten and published in 2009. These changes will include adding the Critical Manufacturing sector and its SSA to those sections of the NIPP where sectors and their SSAs are listed, referenced, or PO 00000 Frm 00050 Fmt 4703 Sfmt 4703 described, and amending the last sentence of the definition of ‘‘Sector’’ in the Glossary to read, ‘‘The NIPP addresses the 17 CIKR sectors enumerated in HSPD–7 and any additional sectors created by the Secretary of Homeland Security pursuant to HSPD–7.’’ FOR FURTHER INFORMATION CONTACT: Larry L. May, Deputy Director, NIPP Program Office, Partnership and Outreach Division, Office of Infrastructure Protection, National Protection and Programs Directorate, Department of Homeland Security, Washington, DC 20528, 703–235–3648 or NIPP@dhs.gov. Dated: September 17, 2008. R. James Caverly, Director, Partnership and Outreach Division, Office of Infrastructure Protection, Department of Homeland Security. [FR Doc. E8–22609 Filed 9–25–08; 8:45 am] BILLING CODE 4410–10–P DEPARTMENT OF HOMELAND SECURITY U.S. Customs and Border Protection Notice of Issuance of Final Determination Concerning Certain Mesh Dressing U.S. Customs and Border Protection, Department of Homeland Security. ACTION: Notice of final determination. AGENCY: SUMMARY: This document provides notice that U.S. Customs and Border Protection (‘‘CBP’’) has issued a final determination concerning the country of origin of certain mesh dressing known as TegadermTM Ag Mesh Dressing. Based upon the facts presented, CBP has concluded in the final determination that the United States is the country of origin of the TegadermTM Ag Mesh Dressing for purposes of U.S. Government procurement. DATES: The final determination was issued on September 22, 2008. A copy of the final determination is attached. Any party-at-interest, as defined in 19 CFR 177.22(d), may seek judicial review of this final determination within October 27, 2008. FOR FURTHER INFORMATION CONTACT: Cynthia Reese, Valuation and Special Programs Branch, Regulations and Rulings, Office of International Trade (202–572–8812). SUPPLEMENTARY INFORMATION: Notice is hereby given that on September 22, 2008, pursuant to subpart B of part 177, Customs and Border Protection (CBP) E:\FR\FM\26SEN1.SGM 26SEN1

Agencies

[Federal Register Volume 73, Number 188 (Friday, September 26, 2008)]
[Notices]
[Pages 55859-55860]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-22611]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES


National Institutes of Health

Prospective Grant of Exclusive License: Use of Benztropinamine 
Analogs To Treat Psychiatric and Neurological Disorders

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 
CFR Part 404.7(a)(1)(i), that the National Institutes of Health, 
Department of Health and Human Services, is contemplating the grant of 
an exclusive patent license to practice the inventions embodied in U.S. 
Patent Application No. 60/689,746, filed June 10, 2005, now abandoned 
[HHS Ref. No. E-089-2005/0-US-01]; PCT Patent Application No. PCT/
US2006/22401, filed June 7, 2006, now abandoned [HHS Ref. No. E-089-
2005/0-US-02]; U.S. Patent Application No. 11/917,036, filed December 
10, 2007 [HHS Ref. No. E-089-2005/0-US-03]; European Patent Application 
No. 06772641.4, filed December 7, 2007, which published as 1888064 on 
February 20, 2008 [HHS Ref. No. E-089-2005/0-EP-04]; Australian Patent 
Application No. 2006258035, filed November 30, 2007 [HHS Ref. No. E-
089-2005/0-AU-05]; Japanese Patent Application No. 2008-515947, filed 
December 7, 2007 [HHS Ref. No. E-089-2005/0-JP-06]; and Canadian Patent 
Application No. 2609577, filed November 23, 2007 [HHS Ref. No. E-089-
2005/0-CA-07], all of which are entitled ``Benztropinamine Analogs as 
Dopamine Uptake Inhibitors'' (Inventors: Amy Newman and Jonathan Katz, 
NIDA) to Shire LLC, having an office in at least Basingstoke, United 
Kingdom. The patent rights in these inventions have been assigned to 
the United States of America.
    The prospective exclusive license territory may be worldwide, and 
the field of use may be limited to the use of benztropinamine analogs,

[[Page 55860]]

specifically, compounds derived from Formula I, wherein B is NR \4\ and 
wherein R \4\ is not CH3 (methyl group) to treat psychiatric 
and neurological disorders.

DATES: Only written comments and/or applications for a license which 
are received by the NIH Office of Technology Transfer on or before 
November 25, 2008 will be considered.

ADDRESSES: Requests for copies of the patent application, inquiries, 
comments, and other materials relating to the contemplated exclusive 
license should be directed to: Charlene A. Sydnor, Ph.D., Technology 
Licensing Specialist, Office of Technology Transfer, National 
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, 
MD 20852-3804; Telephone: (301) 435-4689; Facsimile: (301) 402-0220; e-
mail: sydnorc@mail.nih.gov.

SUPPLEMENTARY INFORMATION: This technology relates to the synthesis of 
novel dopamine transport inhibitors and their use to treat mental 
disorders. The inventors developed benztropinamine analogs by replacing 
the benzhydrylether moiety of benztropine and its analogs with the 
isosteric benzhydrylamine system in order to produce more stable 
compounds with increased solubility and bioavailability for improved 
therapeutic formulation and utility. These compounds have a high 
affinity for the dopamine transporter and inhibit dopamine uptake, but 
do not produce a significant stimulation of locomotor activity or 
cocaine-like subjective effects in a drug discrimination model. These 
compounds are useful for the treatment of mental disorders such as 
conduct disorders, alcohol addiction, tobacco addiction, nicotine 
addiction, drug addiction, sleep disorders, inhalation disorders, 
Parkinsonism including Parkinson's disease, female and male orgasmic 
disorders, female and male sexual arousal disorders, hypoactive sexual 
desire disorders, and anxiety and/or depression disorders. These 
compounds are also useful as imaging probes for detecting cocaine 
binding sites, as well as monitoring or diagnosing Parkinson's disease.
    The prospective exclusive license will be royalty bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR Part 
404.7. The prospective exclusive license may be granted unless within 
sixty (60) days from the date of this published notice, the NIH 
receives written evidence and argument that establishes that the grant 
of the license would not be consistent with the requirements of 35 
U.S.C. 209 and 37 CFR Part 404.7.
    Applications for a license in the field of use filed in response to 
this notice will be treated as objections to the grant of the 
contemplated exclusive license. Comments and objections submitted to 
this notice will not be made available for public inspection and, to 
the extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552.

    Dated: September 17, 2008.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
[FR Doc. E8-22611 Filed 9-25-08; 8:45 am]
BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.